GSK plc (GLAXF)
| Market Cap | 100.25B +33.9% |
| Revenue (ttm) | 43.29B +4.0% |
| Net Income | 7.70B +84.9% |
| EPS | 1.88 +86.6% |
| Shares Out | n/a |
| PE Ratio | 13.02 |
| Forward PE | 9.86 |
| Dividend | 0.88 (3.50%) |
| Ex-Dividend Date | Feb 19, 2026 |
| Volume | 453 |
| Average Volume | 1,842 |
| Open | 25.56 |
| Previous Close | 25.01 |
| Day's Range | 25.26 - 25.56 |
| 52-Week Range | 17.15 - 31.48 |
| Beta | 0.30 |
| RSI | 41.29 |
| Earnings Date | Apr 29, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK plc's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial numbers in GBP Financial StatementsNews
Halozyme announces global collaboration and license agreement with GSK
Halozyme Therapeutics (HALO) announced the company entered into a global collaboration and license agreement with GSK (GSK). Under the collaboration, GSK has licensed Halozyme’s ENHANZE drug delivery ...
GSK partners with Julie Bowen, Ty Burrell to raise meningitis awareness
GSK (GSK) announced new campaign spokespeople, Julie Bowen and Ty Burrell, as part of its Ask2BSure public health campaign to raise awareness and encourage parents to “ask to be sure”
Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults
PHILADELPHIA--(BUSINESS WIRE)-- #Adolescents--Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults.
GSK price target lowered to 2,100 GBp from 2,250 GBp at Citi
Citi lowered the firm’s price target on GSK (GSK) to 2,100 GBp from 2,250 GBp and keeps a Neutral rating on the shares.
Big Pharma M&A set for mega year as patent expiries drive deal urgency
Biotech dealmaking is on pace for a bumper year in 2026, with large drugmakers on an acquisition spree to boost their pipelines ahead of upcoming patent losses.
GSK Canada secures priority review for regulatory submission of bepirovirsen, a potential functional cure treatment for chronic hepatitis B
The new drug submission for bepirovirsen was granted priority review, underscoring the unmet need for patients Submission supported by statistically significant and clinically meaningful functional cu...
GSK PLC (GSK) Q1 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Pipeline Expansion
GSK PLC (GSK) Q1 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Pipeline Expansion
Q1 2026 GSK plc Earnings Call Transcript
Q1 2026 GSK plc Earnings Call Transcript
GSK Faces Setback as Nivisnebart Trial for Alzheimer's Discontinued
GSK Faces Setback as Nivisnebart Trial for Alzheimer's Discontinued
A Look at GSK PLC (GSK) After 5.6% Decline -- GF Value $43.80 vs Price $51.40
A Look at GSK PLC (GSK) After 5.6% Decline -- GF Value $43.80 vs Price $51.40
Big pharma can boost Britain: Labour must not let our flagship firms drift away, says RUTH SUNDERLAND
One area where the UK still performs well on an international stage is pharmaceuticals, led by AstraZeneca and GSK.
AstraZeneca (AZN) and GSK Report Strong Q1 Earnings Amid Pricing Policy Concerns
AstraZeneca (AZN) and GSK Report Strong Q1 Earnings Amid Pricing Policy Concerns
GSK Reports Strong Q1 2026 Results with Revenue Growth
GSK Reports Strong Q1 2026 Results with Revenue Growth
GSK Declares Quarterly Dividend of $0.44, Initiates £2 Billion Buyback
GSK Declares Quarterly Dividend of $0.44, Initiates £2 Billion Buyback
GSK Raises 2031 Sales Forecast to Over GBP 40 Billion
GSK Raises 2031 Sales Forecast to Over GBP 40 Billion
GSK Expects Steady Growth Through 2026
GSK Expects Steady Growth Through 2026
GSK Reports Strong Q1 Sales Growth and Advancements in R&D
GSK Reports Strong Q1 Sales Growth and Advancements in R&D
AstraZeneca (AZN) and GlaxoSmithKline (GSK) Exceed Q1 Earnings Expectations
AstraZeneca (AZN) and GlaxoSmithKline (GSK) Exceed Q1 Earnings Expectations
Shot in the arm for GSK and AstraZeneca from cancer drug sales
The blue chip drug makers saw first quarter earnings beat market expectations.
GSK plc Earnings Call Transcript: Q1 2026
Q1 2026 saw 5% sales growth to £7.6B, led by Specialty Medicines and Shingrix. Operating profit rose 10%, EPS 9%, and cash generation was strong. Guidance for profitable growth is confirmed, with pipeline acceleration and disciplined capital allocation ongoing.
Vaccine Star Shingrix Lifts GSK, But Weak Segments Raise Eyebrows
British pharmaceutical company GSK Plc (NYSE: GSK) on Wednesday reported first-quarter core earnings of $1.25 per share (46.5 pence), beating the consensus estimate of $1.17. Earnings rose 4%, or 9% ...
GSK reaffirms 2031 sales outlook over GBP 40B
06:10 EDT GSK (GSK) reaffirms 2031 sales outlook over GBP 40B
GSK reports Q1 core EPS 46.5p, up 9% at CER
Reports total Q1 sales GBP 7.6B +2% AER; +5% CER. Luke Miels, CEO, said, “GSK (GSK) has made a strong start to 2026, with good performance from our key growth
Cancer drug demand helps AstraZeneca and GSK boost their bottom lines
Pharmaceutical drug giants AstraZeneca and GSK both saw cancer drug sales rise in their latest quarter.